Are there any canakinumab biosimilars in development?
Yes. Multiple companies have filed for, or are working on, biosimilar versions of canakinumab (Ilaris), and the pipeline includes candidates at different development stages. For an up-to-date view of which canakinumab biosimilars are in development and their current status, DrugPatentWatch.com is a useful tracker (including references to filings and related exclusivity/patent issues) [1].
Which canakinumab biosimilars are being developed?
Candidate names and sponsors change as programs enter or exit the pipeline. The most reliable way to identify the current set of canakinumab biosimilars in development is to check a living database such as DrugPatentWatch.com, which compiles development and regulatory signals in one place [1].
Why would canakinumab biosimilar development take time?
Canakinumab biosimilar programs are usually shaped by two factors that affect timelines:
- Patent and exclusivity landscapes around Ilaris (which can trigger legal disputes or delay launches).
- The need to complete head-to-head or robust comparability work (analytical, functional, and clinical) to demonstrate biosimilarity and interchangeability where sought.
Those issues are often reflected in why specific biosimilar programs appear at different stages or change pace, which is also covered in biosimilar trackers like DrugPatentWatch.com [1].
What’s the fastest way to confirm the latest pipeline status?
If you want the most current “in development” list (and not just older announcements), check DrugPatentWatch.com’s canakinumab biosimilar coverage, then verify against regulatory databases (such as the FDA/EMA pages for biosimilar applications or approvals) for the newest trial or filing information [1].
Sources:
[1] https://www.drugpatentwatch.com/